The results contribute novel insights into the potential role of sCD36 in DKD progression and therapeutic monitoring.1, we found that sCD36 levels were significantly reduced in the GLP-1RA group, and this reduction was positively correlated with improvement in urinary albumin-to-creatinine ratio (UACR), highlighting a strong association between sCD36 and renal function in DKD.2, based on prior literature, we propose that GLP-1RAs may exert renoprotective effects by modulating CD36-related molecular pathways, potentially reducing renal lipotoxicity and inflammation. Here, CD36 is linked to diabetic kidney disease.